CA2007913A1 - Compose et traitement avec une combinaison de peptides - Google Patents

Compose et traitement avec une combinaison de peptides

Info

Publication number: CA2007913A1
Authority: CA; Canada
Prior art keywords: peptide; derivative; analogue; pgla; administered
Prior art date: 1989-01-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002007913A

Other languages

English (en)

Inventor

Michael Zasloff

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Childrens Hospital of Philadelphia CHOP

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-30

Filing date

1990-01-17

Publication date

1990-07-30

1990-01-17 Application filed by Individual filed Critical Individual

1990-07-30 Publication of CA2007913A1 publication Critical patent/CA2007913A1/fr

Status Abandoned legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 51
239000000203 mixture Substances 0.000 title claims abstract description 26
101800004819 PGLa Proteins 0.000 claims abstract description 45
108060003100 Magainin Proteins 0.000 claims abstract description 37
238000000034 method Methods 0.000 claims description 25
241000894006 Bacteria Species 0.000 claims description 9
210000004027 cell Anatomy 0.000 claims description 8
241000233866 Fungi Species 0.000 claims description 4
230000037396 body weight Effects 0.000 claims 3
210000004881 tumor cell Anatomy 0.000 claims 1
235000001014 amino acid Nutrition 0.000 description 30
229940024606 amino acid Drugs 0.000 description 30
150000001413 amino acids Chemical class 0.000 description 29
MGIUUAHJVPPFEV-ABXDCCGRSA-N magainin ii Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 MGIUUAHJVPPFEV-ABXDCCGRSA-N 0.000 description 16
101800004761 Magainin-2 Proteins 0.000 description 14
230000002209 hydrophobic effect Effects 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
238000002360 preparation method Methods 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
230000000813 microbial effect Effects 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
OFIZOVDANLLTQD-ZVNXOKPXSA-N magainin i Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 OFIZOVDANLLTQD-ZVNXOKPXSA-N 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
239000006137 Luria-Bertani broth Substances 0.000 description 2
101500009721 Xenopus laevis Magainin-2 Proteins 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
235000010633 broth Nutrition 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
-1 injectable solution Substances 0.000 description 2
108091005128 magainin I Proteins 0.000 description 2
239000012528 membrane Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
241000192041 Micrococcus Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003915 cell function Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000934 spermatocidal agent Substances 0.000 description 1
230000001150 spermicidal effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Marine Sciences & Fisheries (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CA002007913A 1989-01-30 1990-01-17 Compose et traitement avec une combinaison de peptides Abandoned CA2007913A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US30298589A	1989-01-30	1989-01-30
US302,985		1989-01-30
US34689489A	1989-05-03	1989-05-03
US346,894		1989-05-03

Publications (1)

Publication Number	Publication Date
CA2007913A1 true CA2007913A1 (fr)	1990-07-30

Family

ID=26973198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002007913A Abandoned CA2007913A1 (fr)	1989-01-30	1990-01-17	Compose et traitement avec une combinaison de peptides

Country Status (5)

Country	Link
EP (1)	EP0455719A4 (fr)
JP (1)	JPH04506056A (fr)
AU (1)	AU5042890A (fr)
CA (1)	CA2007913A1 (fr)
WO (1)	WO1990008552A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU648140B2 (en) *	1991-02-01	1994-04-14	Virtual Drug Development, Inc.	Reverse antimicrobial peptides and antimicrobial compositions
WO1992022317A1 (fr) *	1991-06-12	1992-12-23	Magainin Pharmaceuticals, Inc.	Composition de peptides biologiquement actifs presentant des substitutions au niveau de leur terminaison c et traitement a l'aide de ces peptides
US5593866A (en) *	1992-08-21	1997-01-14	The University Of British Columbia	Cationic peptides and method for production
US6057291A (en)	1995-06-02	2000-05-02	University Of British Columbia	Antimicrobial cationic peptides
AU6940796A (en)	1995-08-23	1997-03-19	University Of British Columbia, The	Antimicrobial cationic peptides and methods of screening for the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0362209B1 (fr) *	1987-03-04	1994-06-08	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Composes bioactifs synthetiques nouveaux et procede d'obtention d'effets bioactifs

1990
- 1990-01-17 CA CA002007913A patent/CA2007913A1/fr not_active Abandoned
- 1990-01-25 WO PCT/US1990/000460 patent/WO1990008552A1/fr not_active Ceased
- 1990-01-25 AU AU50428/90A patent/AU5042890A/en not_active Abandoned
- 1990-01-25 EP EP19900902924 patent/EP0455719A4/en not_active Withdrawn
- 1990-01-25 JP JP2503427A patent/JPH04506056A/ja active Pending

Also Published As

Publication number	Publication date
JPH04506056A (ja)	1992-10-22
EP0455719A4 (en)	1992-07-08
WO1990008552A1 (fr)	1990-08-09
AU5042890A (en)	1990-08-24
EP0455719A1 (fr)	1991-11-13

Legal Events

Date	Code	Title	Description
1996-07-17	FZDE	Dead

Publication	Publication Date	Title
US6875744B2 (en)	2005-04-05	Short bioactive peptides
EP1379265A2 (fr)	2004-01-14	Peptides bioactifs courts et leurs procedes d'utilisation
EP0667871A4 (fr)	1995-04-06	Compositions peptidiques amphiphiles biologiquement actives et utilisations desdites compositions.
US5235038A (en)	1993-08-10	Deletion and substitution analogues of melittin peptide
US5217956A (en)	1993-06-08	Composition and treatment with biologically active peptides and certain anions
US5073542A (en)	1991-12-17	CPF peptide compositions and their use in inhibiting growth of target cells or a virus
KR101700603B1 (ko)	2017-02-14	바퀴벌레에서 유래한 항균 펩타이드 페리플라네타신-1 및 그의 조성물
AU5541694A (en)	1994-05-24	Novel biologically active peptides and uses therefor
AU1782992A (en)	1992-11-02	Novel peptide compositions and uses therefor
KR101667535B1 (ko)	2016-10-20	왕지네로부터 분리한 항균 펩타이드 스콜로펜드라신-6 및 그의 조성물
KR101740551B1 (ko)	2017-06-08	벼메뚜기에서 유래한 항균 펩타이드 옥시야신-2 및 그의 조성물
KR101743113B1 (ko)	2017-06-02	벼메뚜기에서 유래한 항균 펩타이드 옥시야신-1 및 그의 조성물
AU641129B2 (en)	1993-09-16	Composition and treatment with biologically active peptides and certain anions
EP0590044A1 (fr)	1994-04-06	Composition de peptides biologiquement actifs presentant des substitutions au niveau de leur terminaison c et traitement a l'aide de ces peptides
EP0455719A4 (en)	1992-07-08	Composition and treatment with peptide combinations
US5254537A (en)	1993-10-19	Composition and treatment with peptide combinations
CA2042468A1 (fr)	1991-11-15	Compositions et traitement de peptides biologiquement actifs contenant des residus d'acides d-amines
KR20180117793A (ko)	2018-10-30	왕귀뚜라미에서 유래한 항균 펩타이드 테레오그릴루신 2 및 그의 조성물
CA2040510A1 (fr)	1991-10-24	Composition et traitement faisant appel a des peptides biologiquement actifs et a des cations toxiques
EP0440688B1 (fr)	1994-09-21	Compositions a base de peptides cpf et leurs utilisations
KR101889403B1 (ko)	2018-08-20	바퀴벌레에서 유래한 항균 펩타이드 페리플라네타신-4 및 그의 조성물
KR101889404B1 (ko)	2018-08-20	바퀴벌레에서 유래한 항균 펩타이드 페리플라네타신-5 및 그의 조성물
KR20170131898A (ko)	2017-12-01	벼메뚜기에서 유래한 항균 펩타이드 옥시야신-4 및 그의 조성물